ALPK1 inhibitor

ALBANY, New York, United States and SHANGHAI, China – May 7, 2026 Drug Farm announced new ophthalmologic and central...

Lisbon, Portugal – March 26, 2026 Abcuro presented results from its Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008)...

Albany, USA & Shanghai, China – March 26, 2026 Drug Farm announced that the U.S. Food and Drug Administration...